One Amgen Center Drive
Thousand Oaks, CA 91320-1799
United States
805 447 1000
https://www.amgen.com
Settore/i: Healthcare
Settore: Drug Manufacturers - General
Impiegati a tempo pieno: 26.700
Nome | Titolo | Retribuzione | Esercitate | Anno di nascita |
---|---|---|---|---|
Mr. Robert A. Bradway | Chairman, CEO & President | 6,24M | N/D | 1963 |
Mr. Peter H. Griffith | Executive VP & CFO | 2,85M | N/D | 1959 |
Mr. Esteban Santos | Executive Vice President of Operations | 2,79M | N/D | 1968 |
Dr. David M. Reese M.D. | Executive VP & Chief Technology Officer | 3,16M | N/D | 1963 |
Mr. Murdo Gordon | Executive Vice President of Global Commercial Operations | 3,01M | N/D | 1967 |
Mr. Matthew C. Busch | Chief Accounting Officer & VP of Finance | N/D | N/D | 1974 |
Mr. Mike Zahigian | Senior VP & Chief Information Officer | N/D | N/D | N/D |
Dr. James E. Bradner M.D. | Executive VP of Research and Development & Chief Scientific Officer | N/D | N/D | 1972 |
Justin G. Claeys | Vice President of Investor Relations | N/D | N/D | N/D |
Mr. Jonathan P. Graham | Executive VP, General Counsel & Secretary | 2,26M | N/D | 1961 |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
L'ISS Governance QualityScore di Amgen Inc. al 1 maggio 2024 è 2. I criteri di valutazione fondamentali sono revisione: 2; Consiglio di Amministrazione: 9; diritti degli azionisti: 1; retribuzione: 2.